Traws Pharma, Inc.
Traws Pharma, Inc. (Nasdaq Capital Market: TRWS) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies targeting critical threats to human health in respiratory viral diseases and select oncology indications. The company was formed through the April 2024 merger of Onconova Therapeutics,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Traws Pharma, Inc. does
In the company’s own words
Traws Pharma, Inc. (Nasdaq Capital Market: TRWS) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies targeting critical threats to human health in respiratory viral diseases and select oncology indications. The company was formed through the April 2024 merger of Onconova Therapeutics, Inc. with Trawsfynydd Therapeutics, Inc., which expanded its focus from cancer therapeutics to include antiviral development.
The company's clinical pipeline comprises four primary programs. Tivoxavir marboxil is an oral, small-molecule cap-dependent endonuclease inhibitor designed as a single-dose treatment for bird flu and seasonal influenza, with preclinical efficacy demonstrated in H5N1 models and Phase 1 data showing favorable tolerability and pharmacokinetics. Ratutrelvir is a 3CL protease inhibitor targeting SARS-CoV-2, with Phase 2 data demonstrating shorter time-to-symptom resolution and fewer adverse events compared to PAXLOVID, including no viral rebound events observed to date. Narazaciclib is a multi-targeted kinase inhibitor targeting CDK4/6, AMPK-related protein kinase 5, and colony-stimulating factor 1 receptor, being developed for solid tumors and hematological malignancies, with ongoing clinical studies in China through a partnership with HanX Biopharmaceuticals. Rigosertib is a polo-like kinase 1 inhibitor being investigated for recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma and other cancers, with preliminary clinical data showing durable responses in a small patient population.
The company maintains intellectual property rights through exclusive licenses and owned patents covering antiviral compounds and compositions, with patent protection extending through 2040 and potential for patent term extensions. Traws has established distribution and commercialization partnerships in multiple territories, including agreements with Knight Therapeutics for Canada and Israel, Specialised Therapeutics Asia for Australia and New Zealand, and Pint International for Latin America. The company incurred research and development expenses of $12.1 million during fiscal year 2025 and operates as a smaller reporting company on the Nasdaq Capital Market. Additional information is available at the company's website.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEWTOWN, PA
- Fiscal year end
- December
- CIK
- 1130598
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Traws Pharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Traws Pharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Traws Pharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Traws Pharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Traws Pharma, Inc.'s last four quarterly filings that the numbers alone won't show?”